Assessment of potential jaw‐tracking advantage using control point sequences of VMAT planning. (6th March 2014)

• Record Type: Journal Article
• Authors: Kim, Jung‐in; Park, Jong Min; Park, So‐Yeon; Choi, Chang Heon; Wu, Hong‐Gyun; Ye, Sung‐Joon
• Is Part Of: Journal of applied clinical medical physics. Volume 15:Number 2(2014)
• Page Start: 160
• Page End: 168
• Publication Date: 2014-03-06
• Subjects: VMAT -- jaw tracking -- OAR saving -- dose reduction -- jaw‐tracking static arc plan; Medical physics -- Periodicals; Clinical medicine -- Periodicals; Health Physics; Clinical Medicine; Electronic journals; Periodicals; Periodicals; Fulltext; Internet Resources; 610.153
• DOI: 10.1120/jacmp.v15i2.4625
• Languages: English
• ISSNs: 1526-9914

Abstract

Abstract : This study aims to evaluate the potential jaw‐tracking advantage using control point sequences of volume volumetric‐modulated arc therapy (VMAT) planning. VMAT plans for patients with prostate and head and neck (H&N) cancers were converted into new static arc (SA) plans. The SA plan consisted of a series of static fields at each control point of the VMAT plan. All other machine parameters of the SA plan were perfectly identical to those of the original VMAT plan. The jaw‐tracking static arc (JTSA) plans were generated with fields that closed the jaws of each SA field into the multileaf collimators (MLCs) aperture. The dosimetric advantages of JTSA over SA were evaluated in terms of a dose‐volume histogram (DVH) of organ at risk (OAR) after renormalizing both plans to make the same target coverage. Both plans were delivered to the MatriXX‐based COMPASS system for 3D volume dose verification. The average jaw size reduction of the JTSA along the X direction was 3.1 ± 0.9 cm for prostate patients and 6.9 ± 1.9 cm for H&N patients. For prostate patients, the organs far from the target showed larger sparing (3.7%—8.1% on aver‐age) in JTSA than the organs adjacent to the target (1.1%—1.5%). For the H&N plans, the mean dose reductions for all organs ranged from 4.3% to 11.9%. The dose reductions were more significant in the dose regions of D 80, D 90, and D 95 than the dose regions of D 5, D 10, and D 20 for all patients. Likewise, the deliverability and reproducibility of jaw‐tracking plan were validated. The measured dosimetric advantage of JTSA over SA coincided with the calculated one above. PACS numbers: 87.55.D‐, 87.55.ne